Covid-19 Vaccine Developer Falls After Report of U.S. Scrutiny

Vaxart tumbled as much as 19% after the New York Times reported that some HHS officials are concerned that companies including Vaxart may be trying to inflate their stock prices by exaggerating their roles in Operation Warp Speed.

• HHS has relayed those concerns to the SEC, the Times said, citing an unidentified senior Trump administration official; the SEC declined to comment to the Times
• The weekend report in the Times also discussed how drug company insiders are selling shares after gains tied to Covid-19 vaccines
• Vaxart told the Times in a statement that it “abides by good corporate governance guidelines ...